Key Highlights

  • Instinct Bio Technical Company Holdings Inc. began trading on Nasdaq under BIOT at last closing, after completing a merger with Relativity Acquisition Corp., a SPAC that had itself been delisted from Nasdaq in 2024.
  • The sharp move appears tied to an extremely thin public float rather than any disclosed clinical, regulatory or commercial catalyst; heavy SPAC redemptions left only tens of thousands of public shares outstanding.
  • Regulatory filings disclose no specific revenue or profit figures for the operating business, and the deal carries the usual de-SPAC risks: dilution, warrant overhang and a sponsor with a history of going-concern warnings.
  • The SPAC partner's own history is a flag.

A newly minted Nasdaq name tops the gainers list

A ticker that appeared near the top of a US gainers screen this week, showing a move of roughly 53% on an unconfirmed figure, belongs to one of the market's freshest listings. The company is Instinct Bio Technical Company Holdings Inc. (NASDAQ:BIOT), which began trading on the Nasdaq Stock Market under the symbol BIOT at last closing, with warrants listed as BIOTW.

The label supplied with the figure, "Instinct Bio Technical," matches the real issuer closely. The verified legal name is Instinct Bio Technical Company Holdings Inc., the public holding company formed to house a Japan-based regenerative medicine and longevity operating business. There is no meaningful discrepancy between the user-supplied name and the true issuer, a rare outcome for tickers pulled from a gainers list.

What matters far more than the name is how this company reached Nasdaq, and what the surrounding filings do and do not disclose. BIOT is not a conventional biotech IPO. It is a de-SPAC: the product of a business combination between the private operating company and Relativity Acquisition Corp., a special-purpose acquisition company that previously traded under the symbol ACQC. Understanding that structure is essential to interpreting both the debut-day move and the risks that come with it.

The company behind the ticker

According to the company's own announcement distributed via GlobeNewswire, Instinct Bio describes itself as an integrated regenerative medicine and longevity platform. Its stated activities span the research, manufacturing and commercialization of regenerative health technologies, stem cell-derived products, wellness solutions and advanced skincare. The business is headquartered in Tokyo, with additional operations cited in Las Vegas and New York and what the company calls an established commercial footprint across Asia.

The operating entity that sits beneath the public holding company was identified in earlier SPAC filings as Instinct Brothers Co., Ltd. The chairman and chief executive is Tomoki Nagano, who framed the listing in promotional terms, describing Nasdaq as not the destination but a launchpad for a mission of helping people live longer, healthier lives. That is marketing language, not a financial disclosure, and investors should read it as such.

The company positions itself against a large addressable market, citing projections that the global longevity and wellness market could grow from roughly $27.6 billion in 2025 to about $67.0 billion by 2035. Market-size figures of this kind describe an opportunity, not a company's revenue, and they say nothing about how much of that market any single firm may capture.

Importantly, the sector framing here is closer to consumer wellness and cosmeceuticals than to a clinical-stage drug developer. The merger proxy referred to the target as operating in the cosmeceutical space. Nothing in the filings reviewed describes an investigational drug advancing through defined clinical phases, an Investigational New Drug application, or a pending regulatory submission for approval. Language around "stem cell-derived products" and "regenerative technologies" should therefore not be read as evidence of an approved therapy or a proven medical treatment. Regenerative-medicine and stem-cell marketing claims frequently outrun the regulatory status of the underlying products, and readers should not assume otherwise absent specific disclosure.

How the deal came together

The combination was not a fast or frictionless process. The Business Combination Agreement was originally and was later amended. Deal valuation figures shifted across the paper trail: an annual report characterized it as roughly a $200 million all-stock transaction at $10.00 per share, the definitive merger proxy valued the target at about $225 million in shares at $10.00, and the closing announcement cited a pro forma enterprise value of approximately $288 million. These differences likely reflect the amended terms and different valuation measures rather than a single clean number, and no independently audited valuation was available in the materials reviewed.

Shareholders approved the combination at a meeting held. The vote itself was lopsided in favor, but the more revealing detail lies in the redemptions. Public holders redeemed shares for cash rather than rolling into the combined company, a common feature of recent de-SPACs. Filings tied to the transaction showed only a small number of public shares remaining and a trust account reduced to a fraction of its original size, figures in the range of a few hundred thousand dollars and tens of thousands of public shares. In other words, most of the cash that a SPAC is supposed to deliver to its target had already walked out the door before the deal closed.

Pro forma ownership underscores who controls the entity. On a no-redemption basis, the merger proxy showed sellers, the Instinct Bio side, holding about 76.5% of the company, the sponsor group about 19.1%, and public stockholders a sliver of roughly 0.2%, out of a total of roughly 28.8 million shares. On a fully diluted basis that includes warrants, the public share rises materially, to roughly a third, which foreshadows meaningful potential dilution if warrants are exercised.

Why the stock may have moved

Here the honest answer is the important one: no definitive, company-specific catalyst was identified to explain a debut-day surge of the reported magnitude. There was no disclosed clinical readout, no regulatory clearance, no earnings report and no new commercial contract accompanying the pop. The event driving the price action appears to be the listing itself.

Thin-float de-SPACs are structurally prone to violent opening moves. When redemptions strip out nearly all of the freely trading public shares, the tradable float can shrink to a very small number, and a modest amount of buying can push the quoted price sharply higher. The ownership math above, with insiders and sellers holding the overwhelming majority of shares and public holders reduced to a tiny slice at closing, is exactly the setup that tends to produce outsized, and often short-lived, percentage swings. That is a mechanical explanation, not a judgment on the underlying business, and it is consistent with the pattern seen across many recent de-SPAC debuts.

Any price figure here should be dated and treated cautiously. The roughly 53% gain came from an undated gainers figure around the July 24 debut; first-day and early quotes for micro-float names can be volatile and are not reliable indicators of sustainable value.

The risks investors should not overlook

The SPAC partner's own history is a flag. Relativity Acquisition Corp. was delisted from Nasdaq in June 2024 and subsequently traded over the counter, with a relisting on Nasdaq made a condition of completing the Instinct deal. Its annual report disclosed a net loss of about $1.2 million for 2025, a working capital deficit exceeding $3 million, repeated deadline extensions and liquidity, listing and timing risks, the kind of going-concern context common to aging shells racing to close before a deadline.

The combined company's disclosures are notably thin on the numbers that matter most. Across the closing announcement, the merger proxy and the annual report reviewed, no specific revenue, net income or profitability figures for the operating business were provided. A company can call itself revenue-generating, as this one does, without the filings quantifying that revenue in the materials available. Investors cannot verify a valuation of $200 million or more against financial results they cannot see.

Conclusion

For a company positioning itself in regenerative medicine, longevity and advanced skincare, the questions that matter are concrete and answerable only through future filings. Investors would want to see audited revenue and margins for the operating business, a clear description of which products are sold today versus which remain in development, and the regulatory status of anything described as a stem-cell or regenerative product. They would also want clarity on how much cash actually reached the combined company after redemptions, since that determines how long it can operate before raising more capital. None of this is exotic; it is the standard disclosure any operating company eventually provides. The gap between an ambitious market-opportunity narrative and this kind of verifiable detail is precisely what separates a durable business from a debut-day trading vehicle, and it is the gap prospective investors should watch most closely in the weeks ahead.

Then there is the standard de-SPAC risk stack. The warrant overhang (BIOTW) implies potential dilution. The trust was largely depleted by redemptions, raising questions about how much cash actually funds operations and whether additional financing, and further dilution, may follow. Micro-float dynamics that lift a stock can reverse just as quickly. And foreign-based operations concentrated in Japan and Asia add disclosure, oversight and currency considerations.

For informed retail investors, BIOT is best understood as a speculative, newly listed micro-cap whose debut move appears driven by structure rather than substance. The central question is not whether the longevity market is large, it may well be, but whether this specific company can convert an ambitious narrative into disclosed, durable financial results. Until the filings answer that, caution is warranted.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.